Plenary Sessions

Get a sneak peek below at the exciting keynote lectures and plenary sessions that will be part of the IPVS 2025 Scientific Program.

All times below are in Bangkok, Thailand Local Time – UTC +7.

*The below content is subject to change.

Thursday, October 23, 2025

OPENING KEYNOTE AND INTRODUCTION TO IPVS 2025

Ending HPV: Lessons learned from HIV

Praphan Phanuphak

Friday, October 24, 2025

PLENARY SESSION 1: Overcoming social and policy barriers to HPV prevention, screening and care among marginalized people.

Co-chairs:
Heather Brandt and Annette Sohn

Challenges to accessing HPV care services among marginalized groups

Adeeba Kamarulzaman

Addressing structural inequities impacting HPV service delivery

Jenny Sherwood

Community leadership in co-delivering and advocating for health equity

Nittaya Phanuphak

Q&A and Panel Discussion

PLENARY SESSION 2: Progress towards immunotherapies that treat HPV infection.

Co-chairs:
Peter Dull and Wichai Termrungruanglert

Immunotherapy to Treat Anogenital Dysplasia: Biology and Pre-Clinical Work

Richard Roden

Immunotherapy to Treat Recurrent Respiratory Papillomatosis

Simon Best

Landscape of Clinical Development for HPV Therapeutic Vaccines

Kiat Ruxrungtham

Q&A and Panel Discussion

Saturday, October 25, 2025

PLENARY SESSION 3: Basic Science Fundamentals: what we know and where we go from here.

Co-chairs:
Karl Munger and Arkom Chaiwongkot

Molecular Mechanisms of HPV Carcinogenesis

Elizabeth White

HPV Immunology Therapeutic Vaccinology

Angelika B. Riemer

HPV Antivirals

Elliot Androphy

Q&A and Panel Discussion

Sunday, October 26, 2025

PLENARY SESSION 4: Harnessing Artificial Intelligence and Real-World Data for HPV Research, Prevention, and Treatment

Co-chairs:
Natcha Phoolcharoen

Real-World Data, Real-World Challenges, and AI-Driven Opportunities in HPV Research

Jiang Bian

AI-Powered Imaging in HPV-Associated Cancers: Enhancing Detection and Treatment Personalization

Jens Kleesiek

Target Trial Emulation for AI-Enhanced Causal Inference in Evaluating Single-Dose 9-Valent HPV Vaccine Effectiveness in the United States

Yi Guo

Q&A and Panel Discussion

CLOSING Ceremony

Hilleman Award Recipient